Maternal-fetal cancer risk assessment of ochratoxin a during pregnancy

Toxins

Volumn 8, Issue 4, 2016, Pages

  Woo, Chit Shing Jackson ^a   El Nezami, Hani ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fetal; Mycotoxin; Ochratoxin A; Pregnancy; Risk assessment

Indexed keywords

MYCOTOXIN; OCHRATOXIN; CARCINOGEN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; DIETARY INTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOTHER FETUS RELATIONSHIP; NONHUMAN; PREGNANCY; RAT; RENAL CLEARANCE; RISK ASSESSMENT; RISK REDUCTION; SOLID PHASE EXTRACTION; URINARY TRACT TUMOR; ANALYSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED; EGYPT; ENVIRONMENTAL EXPOSURE; FETOMATERNAL TRANSFUSION; FOOD CONTAMINATION; KIDNEY TUMOR; MATERNAL EXPOSURE; PRENATAL EXPOSURE;

ANIMALS; CARCINOGENS; EGYPT; ENVIRONMENTAL EXPOSURE; FEMALE; FOOD CONTAMINATION; HUMANS; KIDNEY NEOPLASMS; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; OCHRATOXINS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT;

EID: 84961590473     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8040087     Document Type: Article

References (89)

1. Bhat, R.V.; Miller, J.D. Mycotoxins and food supply. In Food, Nutrition and Agriculture Review 01: Food for the Future; Albert, J.L., Tucker, R., Roland, N., Gigli, H., Eds.; Food and Agriculture Organization (FAO): Rome, Italy, 1991; Volume 1.
2. Kuiper-Goodman, T. Food safety: Mycotoxins and phycotoxins in perspective. In Mycotoxins and Phycotoxins: Developments in Chemistry, Toxicology, and Food Safety: Proceeding of the IX International IUPAC Symposium on Mycotoxins and Phycotoxins; Miraglia, M., van Egmond, H.P., Brera, C., Gilbert, J., Eds.; Alaken, Inc.: Fort Collins, CO, USA, 1998; pp. 25-48.
3. Anderson, L.M.; Diwan, B.A.; Fear, N.T.; Roman, E. Critical windows of exposure for children's health: Cancer in human epidemiological studies and neoplasms in experimental animal models. Environ. Health Perspect. 2000, 108, 573-594. [CrossRef] [PubMed]
4. Godschalk, R.W.; Kleinjans, J.C. Characterization of the exposure-disease continuum in neonates of mothers exposed to carcinogens during pregnancy. Basic Clin. Pharmacol. Toxicol. 2008, 102, 109-117. [CrossRef] [PubMed]
5. Perera, F.P.; Jedrychowski, W.; Rauh, V.; Whyatt, R.M. Molecular epidemiologic research on the effects of environmental pollutants on the fetus. Environ. Health Perspect. 1999, 107, 451-460. [CrossRef] [PubMed]
6. Vanhees, K.; de Bock, L.; Godschalk, R.W.L.; van Schooten, F.J.; van Waalwijk van Doorn-Khosrovani, S.B. Prenatal exposure to flavonoids: Implication for cancer risk. Toxicol. Sci. 2011, 120, 59-67. [CrossRef] [PubMed]
7. Soffritti, M.; Belpoggi, F.; Tibaldi, E.; Esposti, D.D.; Lauriola, M. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environ. Health Perspect. 2007, 115, 1293-1297. [CrossRef] [PubMed]
8. Wangikar, P.B.; Dwivedi, P.; Sinha, N.; Sharma, A.K.; Telang, A.G. Teratogenic effects in rabbits of simultaneous exposure to Ochratoxin A and Aflatoxin B1 with special reference to microscopic effects. Toxicology 2005, 215, 37-47. [CrossRef] [PubMed]
9. Kuiper-Goodman, T.; Hilts, C.; Billiard, S.M.; Kiparissis, Y.; Richard, I.D.; Hayward, S. Health risk assessment of Ochratoxin A for all age-sex strata in a market economy. Food Addit. Contam. A 2010, 27, 212-240. [CrossRef] [PubMed]
10. Boon, P.E.; Bakker, M.I.; van Klaveren, J.D.; van Rossum, C.T.M. Risk Assessment of the Dietary Exposure to Contaminants and Pesticide Residues in Young Children in the Netherlands; National Institute for Public Health and the Environment: Bilthoven, The Netherlands, 2009.
11. Hallen, I.P.; Breitholtz-Emanuelsson, A.; Hult, K.; Olsen, M.; Oskarsson, A. Placental and lactational transfer of Ochratoxin A in rats. Nat. Toxins 1998, 6, 43-49. [CrossRef]
12. Fukui, Y.; Hoshino, K.; Kameyama, Y.; Yasui, T.; Toda, C.; Nagano, H. Placental transfer of Ochratoxin A and its cytotoxic effect on the mouse embryonic brain. Food Chem. Toxicol. 1987, 25, 17-24. [CrossRef]
13. Appelgren, L.E.; Arora, R.G. Distribution of 14C-labelled Ochratoxin A in pregnant mice. Food Chem. Toxicol. 1983, 21, 563-568. [CrossRef]
14. Ballinger, M.B.; Phillips, T.D.; Kubena, L.F. Assessment of the distribution and elimination of Ochratoxin A in the pregnant rat. J. Food Saf. 1986, 8, 11-24. [CrossRef]
15. Petkova-Bocharova, T.; Stoichev, I.I.; Chernozemsky, I.N.; Castegnaro, M.; Pfohl-Leszkowicz, A. Formation of DNA adducts in tissues of mouse progeny through transplacental contamination and/or lactation after administration of a single dose of ochratoxin a to the pregnant mother. Environ. Mol. Mutagen. 1998, 32, 155-162. [CrossRef]
16. Zimmerli, B.; Dick, R. Determination of Ochratoxin A at the PPT level in human blood, serum, milk and some foodstuffs by high-performance liquid chromatography with enhanced fluorescence detection and immunoaffinity column cleanup: Methodology and swiss data. J. Chromatogr. B Biomed. Appl. 1995, 666, 85-99. [CrossRef]
17. Postupolski, J.; Karlowski, K.; Kubik, P. Ochratoxin A in maternal and foetal blood and in maternal milk. Rocz. Panstw. Zakl. Hig. 2006, 57, 23-30. [PubMed]
18. Malir, F.; Ostry, V.; Pfohl-Leszkowicz, A.; Novotna, E. Ochratoxin A: Developmental and reproductive toxicity-An overview. Birth Defects Res. B Dev. Reprod. Toxicol. 2013, 98, 493-502. [CrossRef] [PubMed]
19. National Toxicology Program (NTP). Toxicology and Carcinogenesis Studies of Ochratoxin A (CAS No. 303-47-9) in F344/N Rats (Gavage Studies); Department of Health and Human Services: Durham, NC, USA, 1989.
20. Knaap, A.; Anderson, C.; Brantom, P.; Bridges, J.; Crebelli, R.; Greim, H.; Larsen, J.C.; McGregor, D.; Renwick, A.; Schlatter, J. Opinion of the scientific committee on a request from efsa related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA J. 2005, 282, 1-31.
21. Krogh, P.; Gyrd-Hansen, N.; Hald, B.; Larsen, S.; Nielsen, J.P.; Smith, M.; Ivanoff, C.; Meisner, H. Renal enzyme activities in experimental Ochratoxin A-induced porcine nephropathy: Diagnostic potential of phosphoenolpyruvate carboxykinase and gamma-glutamyl transpeptidase activity. J. Toxicol. Environ. Health 1988, 23, 1-14. [CrossRef] [PubMed]
22. Krogh, P.; Elling, F.; Friis, C.; Hald, B.; Larsen, A.E.; Lillehoj, E.B.; Madsen, A.; Mortensen, H.P.; Rasmussen, F.; Ravnskov, U. Porcine nephropathy induced by long-term ingestion of Ochratoxin A. Vet. Pathol. 1979, 16, 466-475. [PubMed]
23. Elling, F. Ochratoxin A-induced mycotoxic porcine nephropathy: Alterations in enzyme activity in tubular cells. Acta Pathol. Microbiol. Scand. A 1979, 87A, 237-243. [CrossRef]
24. Pfohl-Leszkowicz, A.; Bartsch, H.; Azémar, B.; Mohr, U.; Estève, J.; Castegnaro, M. Mesna protects rats against nephrotoxicity but carcinogenicity induced by Ochratoxin A, implicating two separate pathways. FU Med. Biol. 2002, 9, 57-63.
25. Dourson, M.L.; Felter, S.P.; Robinson, D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 1996, 24, 108-120. [CrossRef] [PubMed]
26. Kuiper-Goodman, T. Risk assessment and risk management of mycotoxins in food. In Mycotoxins in Food. Detection and Control; Magan, N., Olsen, M., Eds.; CRC Press LLC: Boca Raton, FL, USA, 2004; pp. 3-31.
27. Benford, D.; Bolger, P.M.; Carthew, P.; Coulet, M.; DiNovi, M.; Leblanc, J.-C.; Renwick, A.G.; Setzer, W.; Schlatter, J.; Smith, B.; et al. Application of the margin of exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem. Toxicol. 2010, 48, S2-S24. [CrossRef] [PubMed]
28. Thuvander, A.; Paulsen, J.E.; Axberg, K.; Johansson, N.; Vidnes, A.; Enghardt-Barbieri, H.; Trygg, K.; Lund-Larsen, K.; Jahrl, S.; Widenfalk, A.; et al. Levels of Ochratoxin A in blood from norwegian and swedish blood donors and their possible correlation with food consumption. Food Chem. Toxicol. 2001, 39, 1145-1151. [CrossRef]
29. Biasucci, G.; Calabrese, G.; Di Giuseppe, R.; Carrara, G.; Colombo, F.; Mandelli, B.; Maj, M.; Bertuzzi, T.; Pietri, A.; Rossi, F. The presence of Ochratoxin A in cord serum and in human milk and its correspondence with maternal dietary habits. Eur. J. Nutr. 2010, 50, 211-218. [CrossRef] [PubMed]
30. Muñoz, K.; Vega, M.; Rios, G.; Muñoz, S.; Madariaga, R. Preliminary study of Ochratoxin A in human plasma in agricultural zones of chile and its relation to food consumption. Food Chem. Toxicol. 2006, 44, 1884-1889. [CrossRef] [PubMed]
31. Miraglia, M.; Brera, C.; Colatosti, M. Application of biomarkers to assessment of risk to human health from exposure to mycotoxins. Microchem. J. 1996, 54, 472-477. [CrossRef] [PubMed]
32. Gilbert, J.; Brereton, P.; MacDonald, S. Assessment of dietary exposure to Ochratoxin A in the UK using a duplicate diet approach and analysis of urine and plasma samples. Food Addit. Contam. 2001, 18, 1088-1093. [CrossRef] [PubMed]
33. Breitholtz, A.; Olsen, M.; Dahlback, A.; Hult, K. Plasma Ochratoxin A levels in three swedish populations surveyed using an ion-pair HPLC technique. Food Addit. Contam. 1991, 8, 183-192. [CrossRef] [PubMed]
34. Merlo, D.F.; Wild, C.P.; Kogevinas, M.; Kyrtopoulos, S.; Kleinjans, J. Newgeneris: A european study on maternal diet during pregnancy and child health. Cancer Epidemiol. Biomark. Prev. 2009, 18, 5-10. [CrossRef] [PubMed]
35. Vähäkangas, K.; Myllynen, P. Experimental methods to study human transplacental exposure to genotoxic agents. Mutat. Res. 2006, 608, 129-135. [CrossRef] [PubMed]
36. Woo, C.S.; Partanen, H.; Myllynen, P.; Vahakangas, K.; El-Nezami, H. Fate of the teratogenic and carcinogenic Ochratoxin A in human perfused placenta. Toxicol. Lett. 2012, 208, 92-99. [CrossRef] [PubMed]
37. Appelgren, L.E.; Arora, R.G. Distribution studies of 14C-labelled aflatoxin B1 and Ochratoxin A in pregnant mice. Vet. Res. Commun. 1983, 7, 141-144. [CrossRef] [PubMed]
38. Gluckman, P.D.; Hanson, M.A.; Cooper, C.; Thornburg, K.L. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 2008, 359, 61-73. [CrossRef] [PubMed]
39. Pallapies, D. Trends in childhood disease. Mutat. Res. 2006, 608, 100-111. [CrossRef] [PubMed]
40. Loebstein, R.; Lalkin, A.; Koren, G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 1997, 33, 328-343. [CrossRef] [PubMed]
41. Morgan, D.J. Drug disposition in mother and foetus. Clin. Exp. Pharmacol Physiol. 1997, 24, 869-873. [CrossRef] [PubMed]
42. Steyn, P.S. Mycotoxins, general view, chemistry and structure. Toxicol. Lett. 1995, 82-83, 843-851. [CrossRef]
43. Miraglia, M.; Brera, C. Task 3.2.7 Assessment of Dietary Intake of Ochratoxin A by the Population of EU Member States; Istituto Superiore di Sanità: Rome, Italy, 2002; pp. 1-153.
44. Pfohl-Leszkowicz, A.; Manderville, R.A. Ochratoxin A: An overview on toxicity and carcinogenicity in animals and humans. Mol. Nutr. Food Res. 2007, 51, 61-99. [CrossRef] [PubMed]
45. Scott, P.M. Biomarkers of human exposure to Ochratoxin A. Food Addit. Contam. 2005, 22, 99-107. [CrossRef] [PubMed]
46. Duarte, S.C.; Pena, A.; Lino, C.M. Human Ochratoxin A biomarkers-From exposure to effect. Crit. Rev. Toxicol. 2011, 41, 187-212. [CrossRef] [PubMed]
47. Ghali, R.; Hmaissia-Khlifa, K.; Mezigh, C.; Ghorberl, H.; Maaroufi, K.; Maschgoul, S.; Hedilli, A. HPLC determination of Ochratoxin A in a low volume of human blood serum. Anal. Lett. 2008, 41, 757-766. [CrossRef]
48. World Health Organization (WHO). IPCS Risk Assessment Terminology; World Health Organization: Geneva, Switzerland, 2004.
49. Lock, E.A.; Hard, G.C. Chemically induced renal tubule tumors in the laboratory rat and mouse: Review of the NCI/NTP database and categorization of renal carcinogens based on mechanistic information. Crit. Rev. Toxicol. 2004, 34, 211-299. [CrossRef] [PubMed]
50. Pfohl-Leszkowicz, A.; Petkova-Bocharova, T.; Chernozemsky, I.N.; Castegnaro, M. Balkan endemic nephropathy and associated urinary tract tumours: A review on aetiological causes and the potential role of mycotoxins. Food Addit. Contam. 2002, 19, 282-302. [CrossRef] [PubMed]
51. Pfohl-Leszkowicz, A.; Tozlovanu, M.; Manderville, R.; Peraica, M.; Castegnaro, M.; Stefanovic, V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Mol. Nutr. Food Res. 2007, 51, 1131-1146. [CrossRef] [PubMed]
52. Pfohl-Leszkowicz, A. Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. Arh. Hig. Rada Toksikol. 2009, 60, 465-483. [CrossRef] [PubMed]
53. Schwartz, G.G. Hypothesis: Does Ochratoxin A cause testicular cancer? Cancer Causes Control 2002, 13, 91-100. [CrossRef] [PubMed]
54. Jennings-Gee, J.E.; Tozlovanu, M.; Manderville, R.; Miller, M.S.; Pfohl-Leszkowicz, A.; Schwartz, G.G. Ochratoxin A: In utero exposure in mice induces adducts in testicular DNA. Toxins 2010, 2, 1428-1444. [CrossRef] [PubMed]
55. Marin-Kuan, M.; Cavin, C.; Delatour, T.; Schilter, B. Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms. Toxicon 2008, 52, 195-202. [CrossRef] [PubMed]
56. Cavin, C.; Delatour, T.; Marin-Kuan, M.; Fenaille, F.; Holzhäuser, D.; Guignard, G.; Bezençon, C.; Piguet, D.; Parisod, V.; Richoz-Payot, J.; et al. Ochratoxin A-mediated DNA and protein damage: Roles of nitrosative and oxidative stresses. Toxicol. Sci. 2009, 110, 84-94. [CrossRef] [PubMed]
57. Mally, A. Ochratoxin A and mitotic disruption: Mode of action analysis of renal tumor formation by Ochratoxin A. Toxicol. Sci. 2012, 127, 315-330. [CrossRef] [PubMed]
58. Manderville, R.A. A case for the genotoxicity of Ochratoxin A by bioactivation and covalent DNA adduction. Chem. Res. Toxicol. 2005, 18, 1091-1097. [CrossRef] [PubMed]
59. Manderville, R.A.; Pfohl-Leszkowicz, A. Bioactivation and DNA adduction as a rationale for Ochratoxin A carcinogenesis. World Mycotoxin J. 2008, 1, 357-367. [CrossRef]
60. Malaveille, C.; Brun, G.; Bartsch, H. Genotoxicity of Ochratoxin A and structurally related compounds in escherichia coli strains: Studies on their mode of action. IARC Sci. Publ. 1991, 261-266.
61. Gillman, I.G.; Clark, T.N.; Manderville, R.A. Oxidation of Ochratoxin A by an FE-porphyrin system: Model for enzymatic activation and DNA cleavage. Chem. Res. Toxicol. 1999, 12, 1066-1076. [CrossRef] [PubMed]
62. Lau, S.S.; Monks, T.J.; Everitt, J.I.; Kleymenova, E.; Walker, C.L. Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone. Chem. Res. Toxicol. 2001, 14, 25-33. [CrossRef] [PubMed]
63. Mally, A.; Dekant, W. DNA adduct formation by Ochratoxin A: Review of the available evidence. Food Addit. Contam. 2005, 22, 65-74. [CrossRef] [PubMed]
64. Mantle, P.G.; Faucet-Marquis, V.; Manderville, R.A.; Squillaci, B.; Pfohl-Leszkowicz, A. Structures of covalent adducts between DNA and Ochratoxin A: A new factor in debate about genotoxicity and human risk assessment. Chem. Res. Toxicol. 2010, 23, 89-98. [CrossRef] [PubMed]
65. Stoev, S.D. Studies on carcinogenic and toxic effects of ochratoxin a in chicks. Toxins 2010, 2, 649-664. [CrossRef] [PubMed]
66. Follmann, W.; Lucas, S. Effects of the mycotoxin Ochratoxin A in a bacterial and a mammalian in vitro mutagenicity test system. Arch. Toxicol. 2003, 77, 298-304. [PubMed]
67. Pfohl-Leszkowicz, A.; Castegnaro, M. Further arguments in favour of direct covalent binding of Ochratoxin A (OTA) after metabolic biotransformation. Food Addit. Contam. 2005, 22, 75-87. [CrossRef] [PubMed]
68. Turesky, R.J. Perspective: Ochratoxin A is not a genotoxic carcinogen. Chem. Res. Toxicol. 2005, 18, 1082-1090. [CrossRef] [PubMed]
69. Tozlovanu, M.; Faucet-Marquis, V.; Pfohl-Leszkowicz, A.; Manderville, R.A. Genotoxicity of the hydroquinone metabolite of Ochratoxin A: Structure-activity relationships for covalent DNA adduction. Chem. Res. Toxicol. 2006, 19, 1241-1247. [CrossRef] [PubMed]
70. Pfohl-Leszkowicz, A.; Gabryelski, W.; Manderville, R.A. Formation of 21-deoxyguanosine-carbon 8-bound ochratoxin a adduct in rat kidney DNA. Mol. Nutr. Food Res. 2009, 53, 154-155. [CrossRef] [PubMed]
71. Hadjeba-Medjdoub, K.; Tozlovanu, M.; Pfohl-Leszkowicz, A.; Frenette, C.; Paugh, R.J.; Manderville, R.A. Structure-activity relationships imply different mechanisms of action for ochratoxin A-mediated cytotoxicity and genotoxicity. Chem. Res. Toxicol. 2012, 25, 181-190. [CrossRef] [PubMed]
72. Pfohl-Leszkowicz, A.; Manderville, R.A. An update on direct genotoxicity as a molecular mechanism of ochratoxin A carcinogenicity. Chem. Res. Toxicol. 2012, 25, 252-262. [CrossRef] [PubMed]
73. Bolt, H.M.; Foth, H.; Hengstler, J.G.; Degen, G.H. Carcinogenicity categorization of chemicals-New aspects to be considered in a european perspective. Toxicol. Lett. 2004, 151, 29-41. [CrossRef] [PubMed]
74. Lima, B.S.; van der Laan, J.W. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul. Toxicol. Pharmacol. 2000, 32, 135-143. [CrossRef] [PubMed]
75. Bendele, A.M.; Carlton, W.W.; Krogh, P.; Lillehoj, E.B. Ochratoxin A carcinogenesis in the (C57BL/6J _ C3H)F1 mouse. J. Natl. Cancer Inst. 1985, 75, 733-742. [PubMed]
76. Boorman, G.A.; McDonald, M.R.; Imoto, S.; Persing, R. Renal lesions induced by Ochratoxin A exposure in the F344 rat. Toxicol. Pathol. 1992, 20, 236-245. [CrossRef] [PubMed]
77. Piekkola, S.; Turner, P.C.; Abdel-Hamid, M.; Ezzat, S.; El-Daly, M.; El-Kafrawy, S.; Savchenko, E.; Poussa, T.; Woo, J.C.S.; Mykkanen, H.; et al. Characterisation of aflatoxin and deoxynivalenol exposure among pregnant egyptian women. Food Addit. Contam. Part A 2012, 29, 962-971. [CrossRef] [PubMed]
78. Polychronaki, N.; Turner, C.P.; Mykkanen, H.; Gong, Y.; Amra, H.; Abdel-Wahhab, M.; El-Nezami, H. Determinants of aflatoxin M1 in breast milk in a selected group of egyptian mothers. Food Addit. Contam. 2006, 23, 700-708. [CrossRef] [PubMed]
79. Zohri, A.A.; Abdel-Gawad, K.M. Survey of mycoflora and mycotoxins of some dried fruits in egypt. J. Basic Microbiol. 1993, 33, 279-288. [CrossRef] [PubMed]
80. Abd Alla, E.-S. Natural occurrence of Ochratoxin A and citrinin in food stuffs in Egypt. Mycotoxin Res. 1996, 12, 41-44. [CrossRef] [PubMed]
81. Hagelberg, S.; Hult, K.; Fuchs, R. Toxicokinetics of Ochratoxin A in several species and its plasma-binding properties. J. Appl. Toxicol. 1989, 9, 91-96. [CrossRef] [PubMed]
82. Schlatter, C.; Studer-Rohr, J.; Rasonyi, T. Carcinogenicity and kinetic aspects of Ochratoxin A. Food Addit. Contam. 1996, 13, 43-44. [PubMed]
83. Frederiksen, M.C. Physiologic changes in pregnancy and their effect on drug disposition. Semin. Perinatol. 2001, 25, 120-123. [CrossRef] [PubMed]
84. Parry, E.; Shields, R.; Turnbull, A.C. Transit time in the small intestine in pregnancy. J. Obstet. Gynaecol. Br. Commonw. 1970, 77, 900-901. [CrossRef] [PubMed]
85. Hunt, J.N.; Murray, F.A. Gastric function in pregnancy. J. Obstet. Gynaecol. Br. Commonw. 1958, 65, 78-83. [CrossRef]
86. Mattison, D.R.; Blann, E.; Malek, A. Physiological alterations during pregnancy: Impact on toxicokinetics. Fundam. Appl. Toxicol. 1991, 16, 215-218. [CrossRef]
87. Anger, G.J.; Costantine, M.M.; Piquette-Miller, M. Chapter 4-Pharmacokinetics in pregnancy. In Reproductive and Developmental Toxicology; Ramesh, C.G., Ed.; Academic Press: San Diego, CA, USA, 2011; pp. 39-45.
88. Dunlop, W.; Davison, J.M. 1 Renal haemodynamics and tubular function in human pregnancy. Baillieres Clin. Obstet. Gynaecol. 1987, 1, 769-787. [CrossRef]
89. Loebstein, R.; Koren, G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther. Drug Monit. 2002, 24, 15-22. [CrossRef] [PubMed]